Academic Journal

Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma

التفاصيل البيبلوغرافية
العنوان: Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma
المؤلفون: Dong, D-N, Fan, P-W, Feng, Y-N, Liu, G-H, Peng, Y-C, Dong, T, Wang, R-Z, Yu, J-M
بيانات النشر: Chinese Medical Association
سنة النشر: 2022
المجموعة: Oxford University Research Archive (ORA)
الوصف: Background The mortality rate among patients with nasopharyngeal carcinoma (NPC) has improved significantly with the advent of chemoradiotherapy strategies. However, distant metastasis remains problematic. Tumor-specific reactivity in cancer patients has been detected exclusively in CD39+ T cells, particularly in CD39+CD103+ T cells. Circulating cancer-specific T cells are important for protecting against metastasis. This study aimed to evaluate the predictive value of circulating CD39+CD8+ T cells for metastasis in patients with NPC. Methods We performed a cross-sectional, longitudinal study of 55 patients with newly diagnosed NPC of stage III–IVa. All patients were initially treated with standard combined chemoradiotherapy. Blood samples were obtained from 24 patients before and at 1 month and 6 months after treatment. T cell expression of CD39 and CD103, together with the markers of T cell exhaustion programmed death-1 (PD-1)/T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) and markers of cell differentiation CD27/CC-chemokine receptor 7/CD45RA, was examined by flow cytometry. The Wilcoxon rank-sum test analysis was used to analyze the differences between two groups. Kaplan-Meier analysis was used for analysis of progression-free survival (PFS). Results The expression of circulating CD39+CD8+ and CD39+CD103+ CD8+ T cells was significantly higher in patients without distant metastasis (CD39+CD8+: 6.52% [1.24%, 12.58%] vs. 2.41% [0.58%, 5.31%], Z=−2.073, P=0.038 and CD39+CD103+CD8+: 0.72% [0.26%, 2.05%] vs. 0.26% [0.12%, 0.64%], Z=−2.313, P = 0.021). Most CD39+ T cells did not express PD-1 or Tim-3. Patients with high expression of CD39+CD103+CD8+ T cells had better PFS than patients with low expression (log rank value = 4.854, P = 0.028). CD39+CD8+ T cells were significantly elevated at 1-month post-treatment (10.02% [0.98%, 17.42%] vs. 5.91% [0.61%, 10.23%], Z = −2.943, P = 0.003). The percentage of advanced differentiated CD8+ T cells also increased at 1-month post-treatment compared with ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
Relation: https://ora.ox.ac.uk/objects/uuid:188e68e8-f3e6-4416-84a2-137f7e407777; https://doi.org/10.1097/cm9.0000000000001745
DOI: 10.1097/cm9.0000000000001745
الاتاحة: https://doi.org/10.1097/cm9.0000000000001745
https://ora.ox.ac.uk/objects/uuid:188e68e8-f3e6-4416-84a2-137f7e407777
Rights: info:eu-repo/semantics/openAccess ; CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)
رقم الانضمام: edsbas.D5F09DAA
قاعدة البيانات: BASE
الوصف
DOI:10.1097/cm9.0000000000001745